B
70.40
-0.54 (-0.76%)
| Previous Close | 70.94 |
| Open | 70.94 |
| Volume | 423,298 |
| Avg. Volume (3M) | 2,922,481 |
| Market Cap | 13,647,945,728 |
| Price / Sales | 27.10 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2026 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 4.0 |
| Insider Activity | -5.0 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.10 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Viking Global Investors Lp | 31 Dec 2025 | 14,393,934 |
| Kohlberg Kravis Roberts & Co. L.P. | 31 Dec 2025 | 13,260,971 |
| Brooklands Fund Management Ltd | 31 Dec 2025 | 2,750,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 125.00 (Evercore ISI Group, 77.56%) | Buy |
| Median | 96.50 (37.07%) | |
| Low | 80.00 (Barclays, 13.64%) | Buy |
| Average | 96.38 (36.90%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 71.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 10 Mar 2026 | 94.00 (33.52%) | Buy | 74.32 |
| Evercore ISI Group | 25 Feb 2026 | 125.00 (77.56%) | Buy | 66.54 |
| Morgan Stanley | 25 Feb 2026 | 98.00 (39.20%) | Buy | 66.54 |
| 06 Jan 2026 | 96.00 (36.36%) | Buy | 73.99 | |
| Oppenheimer | 25 Feb 2026 | 81.00 (15.06%) | Buy | 66.54 |
| 13 Feb 2026 | 83.00 (17.90%) | Buy | 75.25 | |
| Truist Securities | 25 Feb 2026 | 95.00 (34.94%) | Buy | 66.54 |
| 08 Jan 2026 | 86.00 (22.16%) | Buy | 73.82 | |
| HC Wainwright & Co. | 17 Feb 2026 | 100.00 (42.05%) | Buy | 75.85 |
| Wells Fargo | 13 Feb 2026 | 98.00 (39.20%) | Buy | 75.25 |
| 20 Jan 2026 | 88.00 (25.00%) | Buy | 77.19 | |
| Barclays | 28 Jan 2026 | 80.00 (13.64%) | Buy | 77.49 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KUMAR NEIL | - | 68.70 | -80,000 | -5,495,600 |
| VALANTINE HANNAH | - | 74.32 | -8,671 | -644,429 |
| Aggregate Net Quantity | -88,671 | |||
| Aggregate Net Value ($) | -6,140,029 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 70.57 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KUMAR NEIL | Officer | 13 Mar 2026 | Automatic sell (-) | 40,000 | 69.41 | 2,776,400 |
| KUMAR NEIL | Officer | 12 Mar 2026 | Automatic sell (-) | 40,000 | 67.98 | 2,719,200 |
| VALANTINE HANNAH | Director | 10 Mar 2026 | Automatic sell (-) | 8,671 | 74.32 | 644,429 |
| VALANTINE HANNAH | Director | 10 Mar 2026 | Option execute | 8,671 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |